about
The Danish National Multiple Myeloma RegistryNo influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma.Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositisA polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell supportA common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis.Common genetic variants in 11q13.3 and 9q22.33 are associated with molecular subgroups of multiple myelomaGenetic variations in multiple myeloma II: association with effect of treatment.Genetic variations in multiple myeloma I: effect on risk of multiple myeloma.Induction of CD3 delta epsilon omega by phorbol 12-myristate 13-acetate.Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation.Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004.Identification of miRSNPs associated with the risk of multiple myeloma.Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma.Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.Monoclonal antibodies for diagnosis and potential therapy of small cell lung cancer--the ganglioside antigen fucosyl-GM1.Synergy of two human endogenous retroviruses in multiple myeloma.Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium.Gastrin releasing peptide GRP(14-27) in human breast cancer cells and in small cell lung cancer.Production of gastrin-releasing peptide-(18-27) and a stable fragment of its precursor in small cell lung carcinoma cells.Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length.Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.Drug response prediction in high-risk multiple myeloma.Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database.Early relapsed disease of multiple myeloma following up-front HDM-ASCT: a study based on the Danish Multiple Myeloma Registry in the period 2005 to 2014.A common genetic variant in 19q13·3 is associated with outcome of multiple myeloma patients treated with Total Therapy 2 and 3.Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associations--An Extensive Replication of the Associations from the Candidate Gene EraImpact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myelomaPolymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantationThe majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trialsInherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patientsPolymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survivalGenetic variants in theP2RX7gene are associated with risk of multiple myelomaA functional polymorphism in the promoter region of the IL1B gene is associated with risk of multiple myelomaSingle nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomibThe importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAPEarly infections in patients undergoing high-dose treatment with stem cell support: a comparison of patients with non-Hodgkin lymphoma and multiple myeloma
P50
Q28067187-5BC12586-5566-4D7C-983C-B0C05B6A92E6Q33649116-E579FB6A-B4FE-430A-B145-C022FA338F7AQ34669975-EBCA6869-2836-41EA-B17D-07F2A2B7CE56Q34671809-A9A31AA5-B96B-4558-B7CD-473AA25AEDF3Q34677689-27AA3E74-AC8A-4D41-AEFB-1C3F0C38254DQ35212312-648A2682-9980-4830-8D5D-C94A30BC55F7Q37334974-96209790-E06B-4F92-A5BE-CA77F75FB321Q37644812-BFF9B15C-A649-43DE-B36D-18729F6BC6B4Q37671719-35F2A77E-EC27-4D8D-BF43-84D7F5C8CE7BQ37924890-3F0CD26E-95F7-46A9-B61D-7857AF8C3A48Q37924891-1E408ED6-69FD-40B5-B509-A8A513FCEC3DQ38318661-8EDD6F54-B144-4F88-A575-61904959C2BEQ38394274-2976F623-6E4A-426D-A06A-6092B1AFE4D7Q38444697-F88BE6AA-8952-4C3B-9479-8840419EBD2EQ39309897-AE7F59C0-3B74-4BD8-9855-85ED75A606A1Q39679671-69FEAD26-862D-4363-B254-681E5FE3C457Q40165182-C34C1C69-F42F-45B3-AF7A-581C1EF88B08Q40813188-B1FC9C13-0C47-4735-87A0-9C70FCD0E3DAQ41524594-B90AB163-E2A7-4C3C-8A63-DDDF47CC04F1Q41650480-E73A4289-CC42-4612-9514-AB8E71C237B7Q41664164-6B971231-7A5A-4730-8E91-87289A728902Q41733574-0EE3B68A-C4A5-48F0-B921-E6D286A4B40AQ42878211-AAEC630B-3491-4214-87C4-D7028A614384Q46028356-9D65FA47-FDD6-4A83-9546-4FA5FDCC3C0CQ47101456-85E85E9D-570F-46A5-A8F4-887458BDAD9CQ47622541-419E7F23-E3CD-4D97-A432-B74720FB9302Q50564059-360C1AC4-9FA2-4EB6-8BC2-0DFFC4D7846CQ50578063-857E463E-B3E8-446A-AB11-822F2EB50E07Q53185874-C5069929-A4A8-4902-8755-FC327E4F1C1EQ57610426-38A7622E-AAA5-46EB-A4C2-95D822AC083CQ57610455-47E2EB31-0987-484E-98F1-CF6EC46B57FCQ59194314-B8E131B0-C23D-424E-810B-B893D367D649Q59244980-4481E5E3-809D-4199-8689-0EF00A8C5C01Q59244985-9CBB2164-50DD-4944-9C5A-4029B363FB07Q59245028-A86929F1-A71B-407E-B409-5D02A0342CE2Q59245046-A68E5EF1-071A-45C1-819F-A40B1883B53FQ59245051-11FA5935-5485-4753-BFBA-F36B82A13E1AQ59245070-4F77636B-A7F7-4718-A6D6-ACCD29834810Q59245094-02612444-64BC-40F5-B560-DE0AE7D347EDQ59245121-75F6AFEA-F3A0-4A13-9D94-0D5D5480C79F
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Annette J Vangsted
@nl
Annette J Vangsted
@sl
Annette J. Vangsted
@en
Annette J. Vangsted
@es
type
label
Annette J Vangsted
@nl
Annette J Vangsted
@sl
Annette J. Vangsted
@en
Annette J. Vangsted
@es
altLabel
Annette Juul Vangsted
@en
prefLabel
Annette J Vangsted
@nl
Annette J Vangsted
@sl
Annette J. Vangsted
@en
Annette J. Vangsted
@es
P214
P106
P108
P1153
24400272600
P21
P214
P31
P496
0000-0002-2131-731X
P734
P735
P7859
viaf-307282738